What are the manufacturers of Ramucirumab?

Ramucirumab produced by Eli Lilly and Company has been approved in combination with erlotinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. With this approval, ramucizumab now has six approvals from the U.S. Food and Drug Administration (FDA) for the treatment of certain types of lung, liver, stomach and colorectal cancer.

Compared with erlotinib, the ramucirumab combination reduced the risk of disease progression or death by 41% in this patient population. In cancer patients, angiogenesis creates new blood vessels that provide tumors with their own blood supply, allowing them to grow and spread. Some tumors produce a protein called VEGF. These proteins attach to VEGF receptors on blood vessel cells, causing new blood vessels to form around the tumor, thereby promoting growth. Blocking the VEGF protein from binding to receptors located on the surface of blood vessels helps inhibit tumor growth by slowing angiogenesis and the blood supply that nourishes tumors. Of the three known VEGF receptors, VEGF receptor 2 is most closely associated with VEGF-induced tumor angiogenesis.

Ramosizumab is usually an injection preparation. The original drug has been on the market in China, but it has been on the market for a short time and has not been included in the medical insurance. The price of 100mg/10mL per box may be around RMB 5,000, and the price of 500mg/50mL per box may be around RMB 17,000. The price of the original Hong Kong version of 100mg/10mL may be around RMB 8,400 per box, and the price of 500mg/50mL per box may be around RMB 28,000 (the price may fluctuate due to exchange rates), and their pharmaceutical ingredients are basically the same. Currently, there are no generic drugs produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.